Pacira BioSciences (PCRX) Cash from Investing Activities (2010 - 2026)

Pacira BioSciences' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $19.4 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 175.86% year-over-year to $19.4 million; the TTM figure through Mar 2026 stood at $144.6 million (up 254.81% YoY), while the FY2025 annual figure was $99.5 million, up 219.46% from the prior year.
• Cash from Investing Activities was $19.4 million for Q1 2026 at Pacira BioSciences, up from $19.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $66.2 million in Q1 2023 to a low of -$208.0 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged -$6.6 million across 5 years, with a median of $7.3 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities tumbled 1101.36% in 2024, then jumped 5353.53% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at $11.2 million in 2022, then declined by 25.16% to $8.4 million in 2023, then tumbled by 104.39% to -$368000.0 in 2024, then surged by 5353.53% to $19.3 million in 2025, then grew by 0.56% to $19.4 million in 2026.
• The last three Cash from Investing Activities figures came in at $19.4 million (Q1 2026), $19.3 million (Q4 2025), and $43.6 million (Q3 2025), per Business Quant data.